Quantisnow Logo
Dashboard

Allogene Therapeutics Announces Participation in March Investor Conference

$ALLO
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Get the next $ALLO alert in real time by email

Weekly insight reads limit reached.

Join Quantisnow to enjoy unlimited reads, alerts, live feeds, and more.

Meet Quantisnow

Stock alerts. Live news feeds. Press releases. Insider trading. FDA approvals & more.

Get startedLearn more

Invest smarter

A better trading workflow

Access market-moving news before they break out to the general public. Let Quantisnow cut out the noise and only receive insights that matter.

Live feeds
Real-time news feeds for Press Releases, SEC Filings, FDA approvals, market insights and more.
Custom filters
Filter out the noise with company filters, market cap filters, price filters and more.
Audio Squawk
Multitask with confidence and let Quantsinow read breaking news out loud.
Product screenshot
Quantisnow AI Features

Save time

Unlock Insights with AI

Get quick summaries and precise Q&A for every insight, empowering you to make informed decisions without sifting through entire press releases and lengthy SEC filings.

Get alerted immediately

All your stock market alerts in one place

Quantisnow alerts are fast, customizable, and versatile.

Email alerts
Subscribe to your favorite stocks and receive email alerts each time a news pops up.
App notifications
Reduce alerting latency with in-app notifications. Same as email alerts, but faster.
Webhooks
Integrate with Quantisnow programmatically and receive live insights via webhooks
Granular alerts
Want to receive Press Releases but no SEC filings? No problem - Quantisnow alerts are highly customizable and can seemlessly tailor to your trading needs.

Elevate your trading.
Start using Quantisnow today.

Never miss an update.

Get startedLearn more
App screenshot

Simple no-tricks pricing

One membership with full access and no delays.

Quantisnow Plus

Your personal trading assistant for just $39/month.

What's included

  • Live feeds
  • Audio squawk
  • Compact mode in feeds
  • Email alerts
  • App push alerts
  • Unlimited insights reads
  • Unlimited subscriptions
  • Advanced filters in live feeds
  • Support
  • No ads
  • AI-generated summaries and Q&A

One membership - all access

$39/month

Get access

$39/month with yearly billing, $49/month with monthly billing

News insights ingested and delivered in real time
5 million+
Real-time news alerts sent out to Quantisnow users
700,000+
Latency of news delivery pipelines to users via mobile app, webhooks, and email
<100ms
Get the next $ALLO alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$ALLO

DatePrice TargetRatingAnalyst
3/14/2025$5.00Mkt Perform → Mkt Outperform
Citizens JMP
8/8/2024$13.00 → $11.00Outperform
Oppenheimer
5/31/2024$11.00Overweight
Piper Sandler
1/5/2024Mkt Outperform → Mkt Perform
JMP Securities
1/5/2024Buy → Neutral
Guggenheim
12/8/2023$7.00Buy
Citigroup
12/8/2023Buy
Citigroup
6/26/2023$28.00Outperform
Oppenheimer
More analyst ratings

$ALLO
 Press Releases

Fastest customizable press release news feed in the world

See more

  • Allogene Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Update

    Momentum Builds Across Programs with Key Data Milestones Expected in 2025Cemacabtagene Ansegedleucel (Cema-Cel): First-Line (1L) Consolidation in Large B-Cell Lymphoma (LBCL) Ongoing Pivotal Phase 2 ALPHA3 Trial Advancing with Site Activation and Patient EnrollmentLymphodepletion Selection and Futility Analysis Anticipated Around Mid-2025Primary EFS Data Expected Around YE 2026 with Potential BLA Submission in 2027 ALLO-329 in Autoimmune Disease (AID) Secured Investigational New Drug (IND) FDA Clearance for the RESOLUTION Basket Trial in RheumatologyTrial Initiation Targeted for Mid-2025; Proof-of-Concept Data Expected Around YE 2025 ALLO-316 in Renal Cell Carcinoma (RCC) Presented Posi

    $ALLO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

  • Allogene Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update

    Conference Call and Webcast Scheduled for March 13, 2025 at 2:00 p.m. PT/5:00 p.m. ET SOUTH SAN FRANCISCO, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (NASDAQ:ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that it will report the fourth quarter and full year 2024 financial results and provide a business update on March 13, 2025, after the close of the market. The announcement will be followed by a live audio webcast and conference call at 2:00 p.m. PT/5:00 p.m. ET. Listen-Only WebcastThe listen-only webcast will be made available on the Com

    $ALLO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

  • Allogene Therapeutics Announces Participation in March Investor Conference

    SOUTH SAN FRANCISCO, Calif., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (NASDAQ:ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that it will participate in one upcoming investor conference in March. TD Cowen 45th Annual Health Care ConferenceWednesday, March 5, 20258:20AM PT/11:50AM ET Any available webcasts will be posted to the Company's website at www.allogene.com under the Investors tab in the News and Events section. Following a live webcast, a replay will be available on the Company's website for approximately 30 days. About Allogene Therapeutics

    $ALLO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

$ALLO
 Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$ALLO
 Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

See more

$ALLO
 Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$ALLO
 SEC Filings

See more

$ALLO
 Leadership Updates

Live Leadership Updates

See more

  • Artiva Biotherapeutics Appoints Alison Moore, Ph.D., to Its Board of Directors

    SAN DIEGO, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (NASDAQ:ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced the appointment of Alison Moore, Ph.D., as an independent member of its Board of Directors. Dr. Moore brings over 25 years of executive experience in the biotechnology and pharmaceutical industry, including an extensive background in cell therapy manufacturing. She currently serves as Chief Technical Officer (CTO) of Codexis Inc. (NASDAQ:CDXS), a leading enzyme engineering company, and was the former CTO of Allog

    $ALLO
    $ARTV
    $CDXS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Major Chemicals
    Industrials

  • Allogene Therapeutics Appoints Geoffrey Parker as Chief Financial Officer

    SOUTH SAN FRANCISCO, Calif., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (NASDAQ:ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, has appointed Geoffrey Parker as Executive Vice President, Chief Financial Officer. Mr. Parker will oversee the Company's financial operations and business strategy and will serve as a member of the Leadership Team. "Geoff's extensive experience in biotechnology across all aspects of finance and business development strategy will be of tremendous value to Allogene as we advance our critical pipeline assets and explore new opportunities," said David Chang, M.D., Ph.D.

    $ALLO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

  • Allogene Therapeutics Appoints Earl Douglas as General Counsel

    SOUTH SAN FRANCISCO, Calif., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (NASDAQ:ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced that Earl Douglas has been appointed as General Counsel. Mr. Douglas will oversee all aspects of the Company's legal function and serve as a member of the Leadership Team. "We are excited to welcome Earl who brings a tenure of experience guiding publicly-traded biotech companies on complex legal issues, corporate strategy and transactions," said David Chang, M.D., Ph.D., President, Chief Executive Officer and Co-Founder of Allogene. "I also want to th

    $ALLO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

$ALLO
 Financials

Live finance-specific insights

See more

  • Allogene Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Update

    Momentum Builds Across Programs with Key Data Milestones Expected in 2025Cemacabtagene Ansegedleucel (Cema-Cel): First-Line (1L) Consolidation in Large B-Cell Lymphoma (LBCL) Ongoing Pivotal Phase 2 ALPHA3 Trial Advancing with Site Activation and Patient EnrollmentLymphodepletion Selection and Futility Analysis Anticipated Around Mid-2025Primary EFS Data Expected Around YE 2026 with Potential BLA Submission in 2027 ALLO-329 in Autoimmune Disease (AID) Secured Investigational New Drug (IND) FDA Clearance for the RESOLUTION Basket Trial in RheumatologyTrial Initiation Targeted for Mid-2025; Proof-of-Concept Data Expected Around YE 2025 ALLO-316 in Renal Cell Carcinoma (RCC) Presented Posi

    $ALLO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

  • Allogene Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update

    Conference Call and Webcast Scheduled for March 13, 2025 at 2:00 p.m. PT/5:00 p.m. ET SOUTH SAN FRANCISCO, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (NASDAQ:ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that it will report the fourth quarter and full year 2024 financial results and provide a business update on March 13, 2025, after the close of the market. The announcement will be followed by a live audio webcast and conference call at 2:00 p.m. PT/5:00 p.m. ET. Listen-Only WebcastThe listen-only webcast will be made available on the Com

    $ALLO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

  • Allogene Therapeutics Reports Third Quarter 2024 Financial Results and Business Update

    Cemacabtagene Ansegedleucel (Cema-Cel): 1L Consolidation Large B-Cell Lymphoma (LBCL) Pivotal Phase 2 ALPHA3 Trial Continuing with Site Activation and Patient ScreeningLymphodepletion Selection Planned for Mid-2025Enrollment Completion Expected in 1H 2026 with Primary EFS Data by YE 2026Potential BLA Submission in 2027 ALLO-329 in Autoimmune Disease (AID) Pre-Clinical Data Highlighting the Potential of ALLO-329 to be Presented at the American College of Rheumatology (ACR) ConvergenceCD19/CD70 Dual CAR is Specifically Designed to Address Both the B-cell and T-cell Dysfunction Implicated in Autoimmune DiseasesCD70 CAR with Clinically Validated Dagger® Technology Aims to Reduce or Eliminate the

    $ALLO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

$ALLO
 Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more